Skip to main content

Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal

Shares of Merck are down roughly 4% this year, with a market value of roughly $270 billion, making it the third largest pharmaceutical company based in the U.S.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.